DGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Quest Diagnostics Inc (DGX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company demonstrates strong financial performance, positive analyst sentiment, and hedge fund interest. Despite short-term technical weakness, the long-term outlook and fundamentals make it a solid investment choice.
The MACD histogram is -1.87, indicating a bearish trend with negative momentum. RSI is at 16.099, signaling the stock is oversold and may be due for a rebound. Moving averages are converging, suggesting potential consolidation. Key support is at 192.442, and resistance is at 199.296. Overall, the stock is in a short-term downtrend but oversold conditions could lead to a reversal.
Hedge funds are significantly increasing their positions, with a 1536.08% rise in buying activity last quarter.
Analysts have raised price targets, with the highest target at $235 and consistent upgrades across multiple firms.
Strong Q4 financial performance with revenue up 7.06% YoY, net income up 11.36% YoY, and EPS up 14.21% YoY.
Quest Diagnostics serves one in three American adults annually, highlighting its critical role in healthcare.
Gross margin dropped by 1.45% YoY in Q4 2025, which could indicate cost pressures.
Technical indicators show short-term bearish momentum, with MACD and RSI signaling weakness.
No recent congress trading data or AI trading signals to support immediate action.
In Q4 2025, Quest Diagnostics reported revenue of $2.806 billion, up 7.06% YoY. Net income increased to $245 million, up 11.36% YoY. EPS rose to $2.17, up 14.21% YoY. However, gross margin dropped slightly to 31.25%, down 1.45% YoY, indicating some cost pressures.
Analysts are generally positive on DGX, with multiple firms raising price targets recently. The highest target is $235, and the lowest is $210. Ratings range from Neutral to Outperform, with several firms citing strong organic growth, margin expansion, and solid Q4 results as key drivers for optimism.
